Previous Article | Next Article 
Journal of Clinical Microbiology, June 1999, p. 1693-1698, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Use of a Murine O-Antigen-Specific Monoclonal
Antibody To Identify Acinetobacter Strains of Unnamed
Genomic Species 13 Sensu Tjernberg and Ursing
Ralph
Pantophlet,
Lore
Brade, and
Helmut
Brade*
Division of Medical and Biochemical
Microbiology, Research Center Borstel, Center for Medicine and
Biosciences, D-23845 Borstel, Germany
Received 10 December 1998/Returned for modification 28 January
1999/Accepted 22 February 1999
 |
ABSTRACT |
A monoclonal antibody against the O-antigenic polysaccharide chain
of the lipopolysaccharide (LPS) of Acinetobacter strains belonging to the unnamed genomic species 13 Sensu Tjernberg and Ursing
(13TU) was obtained after immunization of BALB/c mice with heat-killed
bacteria and was characterized by enzyme immunoassay and Western blot
analysis, by use of LPS and proteinase K-treated bacterial lysates,
analyses in which the antibody was shown to be highly specific for the
homologous antigen. In addition, when tested in dot and Western blots,
reactivity was observed with 9 of 18 Acinetobacter strains
of genomic species 13TU which had been isolated in Germany and Denmark;
no reactivity was observed with strains of other genomic species,
including the closely related genomic groups 1 (A. calcoaceticus), 2 (A. baumannii), and 3 (unnamed), or
with other gram-negative bacteria. The antibody described here represents a convenient reagent for the simple, economical, and accurate differentiation of clinical isolates of genomic species 13TU
from other Acinetobacter strains. Although the antibody
does not identify all isolates of this genomic group, it is evident that it will be a useful reagent in the development of a serotyping scheme for clinical laboratories.
 |
INTRODUCTION |
The genus Acinetobacter
(Moraxellaceae [26]) is a group of
gram-negative coccobacilli which can be found widespread in nature (18, 32), though most strains have also been isolated from various samples of animal and human origin (8, 11, 18, 27,
28). In general, Acinetobacter strains are not
virulent (2, 18); however, some of them are involved in
severe infections of immunocompromised patients in intensive care units
with increasing frequency (2, 11, 31, 32). The infections
are often difficult to treat, since many of the isolates are highly
resistant to antibiotics (1, 2, 31). However, the importance
of these organisms in hospitals may be underestimated, due to
difficulties in the identification of Acinetobacter strains
to the species level (2, 5, 7, 35). As a result of DNA-DNA
hybridization studies, 20 DNA homology groups (genomic species) have
been delineated, 7 of which have received formal species names (3,
4, 9, 30). Though Acinetobacter baumannii (genomic
species 2) is the most prevalent species associated with outbreaks of
nosocomial infection (2, 11, 31, 32), strains belonging to
the unnamed genomic species 13 Sensu Tjernberg and Ursing (13TU)
(30) have also been isolated from a number of outbreaks
(6, 29). Unfortunately, phenotypic investigations of large
numbers of Acinetobacter strains, validated by DNA homology
studies, have shown that some DNA groups can only be identified
unambiguously by DNA-DNA hybridization techniques (10). This
has been shown to be particularly problematic for species belonging to
the A. calcoaceticus-A. baumannii complex (5,
10), which also includes the clinically relevant genomic species
2 and 13TU. However, DNA-DNA hybridization is laborious and
time-consuming, making it inadequate for use in clinical microbiology laboratories (5). Other molecular identification methods
have been proposed, but most are either too expensive, require too much
experience or standardization, or have simply proven to be unsatisfactorily discriminative (5, 12). Thus, there is
still a need for simple, reliable, and inexpensive identification
methods for Acinetobacter strains, especially for those
belonging to the above-mentioned clinically relevant DNA groups,
methods that can be implemented in clinical microbiology laboratories
(5).
Acinetobacter, like other gram-negative bacteria, contains
lipopolysaccharide (LPS) on the surface of its outer membrane, which in
many strains has been shown to be of the smooth (S) phenotype (13-17, 33, 34). Therefore, we are investigating the
possibility of an identification scheme for Acinetobacter
strains based on the different O antigens within the genus, as has been
done for other bacterial genera (19, 21, 24, 25). For this
purpose, we have started the generation of monoclonal antibodies (MAbs) against the O-antigenic polysaccharide from different
Acinetobacter isolates of clinical and environmental origin.
We report here on the generation and characterization of an MAb
specific for the O-antigen moiety of the LPS of strains belonging to
the unnamed genomic species 13TU, and we evaluate its use as part of an
O-serotyping scheme for the identification of these bacteria at the
species level.
 |
MATERIALS AND METHODS |
Bacteria.
The Acinetobacter strains of genomic
species 13TU investigated in this study (Table
1) consisted of a selection of
representative isolates associated with outbreaks in Germany and in
Denmark, as well as a number of nonoutbreak strains. Additional
Acinetobacter strains, belonging to other genomic species,
were also examined (Table 2). All
isolates had been identified previously to the species level by a wide
variety of methods, including DNA-DNA hybridization, pulsed-field gel
electrophoresis (PFGE) analysis, ribotyping, biotyping, and
electrophoretic protein profiling (6, 29). Epidemiologically
related isolates had identical biotype and ribotype patterns, but in
some cases different PFGE typing patterns were observed
(29). The non-Acinetobacter strains used in this
study were obtained from R. Podschun (National Reference Center of
Klebsiella species, Kiel, Germany) or were from our own
culture collection (Table 2). All bacteria were preserved in 10%
(vol/vol) glycerol broth at
70°C until further use.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Reactivity of MAb S48-13 in dot blot assay with LPS from
proteinase K-treated whole-cell lysates from Acinetobacter
clinical isolates of unnamed genomic species 13TU
|
|
Bacterial LPS, whole-cell lysates, and proteinase K
digestion.
LPS was extracted from Acinetobacter sp.
strain 108 as described previously (33). Preparation of
whole-cell lysates (undiluted or diluted 1:4 in sample buffer
[33]) and proteinase K digestion were performed as
reported previously (23). The samples were used immediately
or otherwise stored at
20°C. In the latter case, they were heated
again at 100°C for 5 min prior to use.
MAb.
The MAb was prepared by conventional protocols after
immunization of mice with heat-killed bacteria.
Acinetobacter sp. strain 108, against which rabbit
hyperimmune sera had been produced in a previous report
(23), was selected in this study for immunization. Four
BALB/c mice were injected intravenously on days 0, 7, 14, and 21 with
20, 20, 60, and 120 µg of antigen, respectively. The mice were
boosted intravenously on day 125 and intraperitoneally on days 126 and
127 with 200 µg of antigen each, followed by fusion on day 129. Primary hybridomas were screened by dot blot and enzyme immunoassay
(EIA) with LPS as antigen. The relevant hybridoma was cloned three
times by limiting dilution, isotyped with a commercially available
isotyping kit (Bio-Rad), and purified by affinity chromatography on
Protein G (Pharmacia). Purity was subsequently checked by Coomassie staining after sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and stored at
20°C.
Serological methods.
EIA and dot and Western blot analyses
were performed as described earlier (23, 33), with purified
LPS or proteinase K-treated bacterial lysates as antigens.
Acid hydrolysis of membrane-bound LPS.
Membrane-bound LPS
was hydrolyzed in 0.1 M HCl as described in a previous study
(22), with minor modifications. Briefly, undiluted bacterial
lysates were treated with proteinase K, subjected to SDS-PAGE, and
subsequently transferred overnight onto a polyvinylidene difluoride
(PVDF) membrane, which was then incubated at 100°C for 1 h in a
heat-resistant glass container containing 0.1 M HCl. After an extensive
washing in blot buffer (33), the membrane was blocked in
blot buffer supplemented with 10% nonfat dry milk and immunostained
with lipid A-specific MAb S1 (20) as described elsewhere
(22). A parallel SDS-polyacrylamide gel was stained with
alkaline silver nitrate as described previously (33).
 |
RESULTS |
Immunization of mice and preparation of MAb.
BALB/c mice were
successfully immunized with heat-killed bacteria from
Acinetobacter sp. strain 108. Animals were tested on day 28 for serum antibodies against the antigen used for immunization by dot
blot assay. The animal exhibiting the strongest reactivity was used for
fusion on day 129. Primary hybridomas (n = 864) were tested by dot blot and by EIA for antibody reactivity, with LPS as
antigen; 10 of these produced specific antibodies. One was finally
selected for further studies on the basis of good reactivity in EIA and
high specificity in the dot blot assay. The antibody (S48-13) was
cloned three times by limiting dilution and was found to be of the
immunoglobulin G1 class. The MAb was purified by using protein G;
purification was ascertained by SDS-PAGE and Coomassie staining (data
not shown). The results described below were obtained with the
affinity-purified antibody.
Specificity of MAb in EIA.
MAb S48-13 was tested by EIA, with
LPS as antigen. Reactivity with the homologous antigen was observed at
a concentration of 2.5 ng of antibody per ml (data not shown). In
addition, checkerboard titrations were performed, with antigen
concentrations of between 32 and 4,000 ng/ml (1.6 to 200 ng of antigen
per well) and antibody concentrations of between 0.5 and 1,000 ng/ml.
The results (Fig. 1) showed that the
antibody exhibits good reactivity with the homologous LPS over a broad
range of antigen concentrations. The specificity of the antibody could
be visualized by Western blot (see below).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Checkerboard titration of MAb S48-13 in EIA with native
LPS from Acinetobacter sp. strain 108 as a solid-phase
antigen. Plates were coated with antigen concentrations of 4,000 ( ),
2,000 ( ), 1,000 ( ), 500 ( ), 250 ( ), 125 ( ), 63 ( ),
and 32 ( ) ng/ml of coating solution (50 µl/well) and reacted with
MAb at the concentrations indicated on the abscissa. OD405,
optical density at 405 nm.
|
|
Reactivity of MAb in dot and Western blots.
When proteinase
K-digested whole-cell lysate or LPS from Acinetobacter sp.
strain 108 was separated by SDS-PAGE, blotted onto a PVDF membrane, and
immunostained with MAb S48-13, a banding pattern typical of an
O-polysaccharide chain could be observed (Fig.
2, lane 1). No staining was observed with
the core lipid A portion when proteinase K-treated lysate was separated
on a 15% gel (data not shown), thus indicating that MAb S48-13 does not react with the core oligosaccharide portion of the LPS molecule and
that the observed banding pattern is not the result of a core-reactive antibody. To confirm that MAb S48-13 is indeed directed against the O
antigen and not another polysaccharide proteinase K-treated bacterial
lysate, which after SDS-PAGE had been immobilized on a PVDF membrane,
was hydrolyzed in 0.1 M HCl, and the membrane-bound 4'-monophosphoryl
lipid A was subsequently detected in situ with lipid A-specific MAb S1.
A ladder-pattern, indistinguishable from that observed following
immunostaining with MAb S48-13, could be observed following
visualization of bands with MAb S1 (data not shown), thus indicating
that the antibody is indeed directed against the O polysaccharide.

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 2.
Reactivity of MAb S48-13 in a Western blot with clinical
isolates of unnamed genomic species 13TU after separation of the
proteinase K-treated whole-cell lysates (10 µl each) by SDS-PAGE on a
10% separating gel. The bacterial lysates are in the following lanes:
1, strain 108; 2, strain 353; 3, strain 387; 4, strain 4419; 5, strain
9894; 6, strain 9836; 7, strain 10716; 8, strain 10717; 9, strain
12112; 10, strain 53937bb; 11, strain 3417; 12, strain 3418; 13, strain
3419; 14, strain 3420; 15, strain 3421; 16, strain St-11681; 17, strain
St-7961; 18, strain St-8195; and 19, strain St-2312.
|
|
To evaluate the possibility of using this antibody as part of a future
O-serotyping scheme for the identification of Acinetobacter genomic species 13TU strains, the antibody was subsequently tested by
dot blot with proteinase K-treated lysates from 11 isolates associated
with outbreaks in Germany and Denmark and with 7 nonoutbreak strains
and was found to react with 4 outbreak and 5 nonoutbreak strains (Fig.
3). The specificity of these reactions
could also be visualized by Western blot (Fig. 2, lanes 2 to 19).
Although most isolates exhibited no difference in banding pattern
compared to that of the homologous strain, a different ladder pattern
could be observed for three strains isolated in Denmark. Comparison of
the core lipid A regions of these strains with that of the homologous
strain in a silver-stained gel (data not shown) showed no differences
in migration distance, thus suggesting that the O antigen of these
three strains is different from that of the other isolates. No
reactivity was observed in the dot blot when MAb S48-13 was tested with
the Acinetobacter strains of other genomic species or with
the non-Acinetobacter strains listed in Table 2 (data not
shown).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 3.
Reactivity of MAb S48-13 with clinical isolates of
unnamed genomic species 13TU in dot blot. Proteinase K-treated
bacterial lysates were diluted 1:3 in distilled water, dotted onto a
nitrocellulose membrane (1 µl per dot), and immunostained. The
bacteria are as follows (from left to right): top row, strains 108, 353, 387, 4419, 9894, 9836, 10716, 10717, and 12112; second row,
strains 53937bb, 3417, 3418, 3419, 3420, 3421, St-11681, St-7961, and
St-8195; and third row, strain St-2312.
|
|
Determination of LPS phenotype by silver staining.
Proteinase
K-treated bacterial lysates from the strains which had not reacted with
MAb S48-13 were subjected to SDS-PAGE, and the gel was subsequently
stained with alkaline silver nitrate. As shown in Fig.
4A, a distinct ladder pattern could be
observed for strains 353 (lane 1), 383 (lane 2), 53937bb (lane 4), 3420 (lane 8), and 3421 (lane 9). However, no banding pattern was observed for the other strains.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 4.
Determination of LPS phenotype after SDS-PAGE on a 10%
gel and staining with alkaline silver nitrate (A) or with MAb S1 in a
Western blot after hydrolysis at 100°C in 0.1 M HCl (B) of proteinase
K-treated bacterial lysates (15 µl each) from strains which had not
reacted with MAb S48-13. Lanes: 1, strain 353; 2, strain 387; 3, strain
4419; 4, strain 53937bb; 5, strain 3417; 6, strain 3418; 7, strain
3419; 8, strain 3420; 9, strain 3421.
|
|
Since the acid hydrolysis method has been shown to be more sensitive
than silver staining (22), all strains were also subjected to hydrolysis in 0.1 M HCl and subsequent immunodetection of the free
lipid A with MAb S1. For those clinical isolates with a banding pattern
in the silver staining (Fig. 4A), an identical pattern was visualized
after immunostaining with MAb S1 (Fig. 4B). However, banding patterns
were also observed for the three other strains which had been negative
after silver staining. Surprisingly, all patterns were identical,
suggesting the presence of only one additional serotype within this
group of strains. The reason for the absence of a banding pattern in
the case of strain 3419 (lane 7) is unclear, but it may be due to a
reduced O-antigen expression or to the production of an LPS which is
naturally of the rough phenotype.
 |
DISCUSSION |
Due to lack of phenotypic methods for the rapid and unambiguous
identification of Acinetobacter strains at the species level (5, 10), we are currently investigating the possibility of an identification for the genus Acinetobacter based on the
O-antigenic polysaccharide of the LPS from these bacteria. Using
hyperimmune rabbit sera, we could show that such a scheme is feasible
(23). However, though they were shown to be highly specific,
the antisera have the disadvantage of containing core-reactive and
non-LPS antibodies, e.g., capsular and protein antibodies, which would lead to false-positive results when the sera are used for
identification purposes (23). MAbs, however, can be
generated which are O antigen specific and thus are more suitable for
such a scheme. Moreover, MAbs have the advantage of being producible in
virtually unlimited amounts.
In this study, a murine MAb was generated against
Acinetobacter strains belonging to the unnamed genomic
species 13TU (30) which, next to genomic species 2 (A. baumannii), is the most frequent DNA group associated with
nosocomial infections in intensive care units (2, 31). The
antibody, S48-13, was characterized by EIA and Western blot analysis
and was found to be highly specific for the O-antigenic polysaccharide
of the homologous LPS. It has been shown in previous studies that
Acinetobacter sp. strain 108 produces S-type LPS (22,
33), and this could be confirmed in our study. MAb S48-13 was
additionally tested by dot and Western blot with 18 other clinical
isolates belonging to unnamed genomic species 13TU, which had been
characterized previously by several methods, including DNA-DNA
hybridization, biotyping, ribotyping, and PFGE. Although
epidemiologically related strains were observed to have identical bio-
and ribotype patterns (6, 29), in some cases differing PFGE
types were noted (29). Reactivity was observed with four
outbreak and five nonoutbreak strains. A different O-antigen banding
pattern was observed for three of the nonoutbreak strains from Denmark
which had reacted positively with MAb S48-13. This is due to the
presence of a chemically different but antigenically related O antigen
in the LPS of these strains compared to that of the other isolates,
since the migration distance of the core lipid A region of these
strains after SDS-PAGE was the same as that of the homologous strain
(data not shown). This will be confirmed by structural analysis.
To determine their LPS phenotype, those strains which had not reacted
with MAb S48-13 were subjected to an acid hydrolysis procedure
(22) in which, after SDS-PAGE and transfer of the LPS onto a
PVDF membrane, the membrane is incubated in an acidic solution at
100°C for 1 h, resulting in the liberation of lipid A which
remains membrane bound and can be detected in situ by using a lipid
A-specific MAb such as S1 (20). Surprisingly, the ladder
patterns observed for these strains were identical, suggesting that
these strains may represent an additional serotype within genomic
species 13TU. The sensitivity of this method is much greater than that
of the silver-staining procedure and has been discussed in detail
elsewhere (22). When SDS-polyacrylamide gels of proteinase
K-digested lysates of the strains which did not react with MAb S48-13
were stained with alkaline silver nitrate, banding patterns were
observed for five strains. However, with the acid hydrolysis method,
O-antigen characteristic patterns could be observed for these five
strains as well as for three additional strains. One isolate, strain
3419, did not show a distinct banding pattern, which is suggestive of a
reduced O-antigen expression or the natural production of LPS of the
rough phenotype.
MAb S48-13 did not react with any Acinetobacter strains
belonging to other genomic species, including the closely related DNA
groups 1, 2, and 3, or with the LPS of strains from several other
gram-negative bacteria, such as Escherichia coli,
Salmonella spp., Shigella sonnei,
Enterobacter spp., Klebsiella pneumoniae, Pseudomonas spp., Stenotrophomonas maltophilia,
Serratia spp., and Proteus spp. Moreover, only
one additional putative serotype was found within the group of isolates
that were investigated, suggesting that Acinetobacter
genomic species 13TU may possibly only consist of a few serotypes.
Thus, a mixture of a few MAbs may become a convenient tool to
definitely identify strains belonging to Acinetobacter DNA
group 13TU.
Although the antibody described in this study does not identify all
clinical isolates, the data show that genomic species 13TU may be, due
to its relatively low degree of diversity, particularly suited for a
serotyping scheme with MAbs. To provide a more comprehensive understanding of the antigenic variations in Acinetobacter O
antigens, we will perform the structural analysis of those antigens
which are not detected by the antibody described here and generate new MAbs to fill the present gap. However, we also need the cooperation of
clinical microbiologists willing to evaluate these antibodies in
various clinical settings in different geographic areas. One should
keep in mind that the well-established serotyping schemes for
Salmonella, Shigella, E. coli, and
other gram-negative human pathogens are extremely helpful tools and
were not established at once.
 |
ACKNOWLEDGMENTS |
We thank L. Dijkshoorn (Leiden University Medical Center, Leiden,
The Netherlands), H. Seifert (Institute of Medical Microbiology and
Hygiene, University of Cologne, Cologne, Germany), and P. Gerner-Smidt
(Department of Clinical Microbiology, Statens Seruminstitut, Copenhagen, Denmark) for providing the Acinetobacter strains
investigated in this study and R. Podschun (National Reference Center
of Klebsiella species, Kiel, Germany) for the
non-Acinetobacter strains. The excellent technical
assistance of V. Susott, D. Brötzmann, S. Ruttkowski, and M. Willen is also gratefully acknowledged.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Medical and Biochemical Microbiology, Research Center Borstel,
Center for Medicine and Biosciences, Parkallee 22, D-23845 Borstel,
Germany. Phone: 49-4537-188474. Fax: 49-4537-188419. E-mail:
hbrade{at}fzborstel.de.
 |
REFERENCES |
| 1.
|
Bergogne-Bérézin, E.
1995.
The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents.
J. Hosp. Infect.
30:441-452.
|
| 2.
|
Bergogne-Bérézin, E., and K. J. Towner.
1996.
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.
Clin. Microbiol. Rev.
9:148-165[Medline].
|
| 3.
|
Bouvet, P. J. M., and P. A. D. Grimont.
1986.
Taxonomy of the genus Acinetobacter with recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., Acinetobacter junii sp. nov., and amended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii.
Int. J. Syst. Bacteriol.
36:228-240[Abstract/Free Full Text].
|
| 4.
|
Bouvet, P. J. M., and S. Jeanjean.
1989.
Delineation of new proteolytic genomic species in the genus Acinetobacter.
Res. Microbiol.
140:291-299[Medline].
|
| 5.
|
Dijkshoorn, L.
1996.
Acinetobacter microbiology, p. 37-69.
In
E. Bergogne-Bérézin, M. L. Joly-Guillou, and K. J. Towner (ed.), Acinetobacter: microbiology, epidemiology, infections, management. CRC Press, Boca Raton, Fla.
|
| 6.
|
Dijkshoorn, L.,
H. M. Aucken,
P. Gerner-Smidt,
M. E. Kaufmann,
J. Ursing, and T. L. Pitt.
1993.
Correlation of typing methods for Acinetobacter isolates from hospital outbreaks.
J. Clin. Microbiol.
31:702-705[Abstract/Free Full Text].
|
| 7.
|
Dijkshoorn, L., and J. van der Toorn.
1992.
Acinetobacter species: which do we mean?
Clin. Infect. Dis.
15:748-749[Medline].
|
| 8.
|
Gennari, M., and P. Lombardi.
1993.
Comparative characterization of Acinetobacter strains isolated from different foods and clinical sources.
Zentbl. Bakteriol.
279:553-564.
|
| 9.
|
Gerner-Smidt, P., and I. Tjernberg.
1993.
Acinetobacter in Denmark. II. Molecular studies of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
APMIS
101:826-832[Medline].
|
| 10.
|
Gerner-Smidt, P.,
I. Tjernberg, and J. Ursing.
1991.
Reliability of phenotypic tests for identification of Acinetobacter species.
J. Clin. Microbiol.
29:277-282[Abstract/Free Full Text].
|
| 11.
|
Grimont, P. A. D., and P. J. M. Bouvet.
1991.
Taxonomy of Acinetobacter, p. 25-36.
In
K. J. Towner, E. Bergogne-Bérézin, and C. A. Fewson (ed.), The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. Plenum Press, New York, N.Y.
|
| 12.
|
Grundmann, H.,
K. J. Towner,
L. Dijkshoorn,
P. Gerner-Smidt,
M. Maher,
H. Seifert, and M. Vaneechoutte.
1997.
Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp.
J. Clin. Microbiol.
35:3071-3077[Abstract].
|
| 13.
|
Haseley, S. R.,
O. Holst, and H. Brade.
1997.
Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter strain 90 belonging to DNA group 10.
Eur. J. Biochem.
245:470-476[Medline].
|
| 14.
|
Haseley, S. R.,
O. Holst, and H. Brade.
1997.
Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter haemolyticus strain ATCC 17906.
Eur. J. Biochem.
244:761-766[Medline].
|
| 15.
|
Haseley, S. R.,
O. Holst, and H. Brade.
1997.
Structural studies of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter (DNA group 11) strain 94 containing 3-amino-3,6-dideoxy-D-galactose substituted by the previously unknown amide-linked L-2-acetoxypropionic acid or L-2-hydroxypropionic acid.
Eur. J. Biochem.
247:815-819[Medline].
|
| 16.
|
Haseley, S. R.,
O. Holst, and H. Brade.
1998.
Structural studies of the O-antigen isolated from the phenol-soluble lipopolysaccharide of Acinetobacter baumannii (DNA group 2) strain 9.
Eur. J. Biochem.
251:189-194[Medline].
|
| 17.
|
Haseley, S. R.,
R. Pantophlet,
L. Brade,
O. Holst, and H. Brade.
1997.
Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter junii strain 65.
Eur. J. Biochem.
245:477-481[Medline].
|
| 18.
|
Juni, E.
1984.
Acinetobacter Brisou and Prevot 1954, 727AL, p. 303-307.
In
N. R. Krieg (ed.), Bergey's manual of systematic bacteriology, vol. I. Williams and Wilkins, Baltimore, Md.
|
| 19.
|
Knirel, Y. A., and N. K. Kochetkov.
1994.
The structure of lipopolysaccharides of gram-negative bacteria. III. The structure of O-antigens: a review.
Biochemistry (Moscow)
59:1325-1383.
|
| 20.
|
Kuhn, H.-M.,
L. Brade,
B. J. Appelmelk,
S. Kusumoto,
E. T. Rietschel, and H. Brade.
1992.
Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.
Infect. Immun.
60:2201-2210[Abstract/Free Full Text].
|
| 21.
|
Orskov, I.,
F. Orskov,
B. Jann, and K. Jann.
1977.
Serology, chemistry, and genetics of O and K antigens of Escherichia coli.
Bacteriol. Rev.
44:667-710.
|
| 22.
|
Pantophlet, R.,
L. Brade, and H. Brade.
1997.
Detection of lipid A by monoclonal antibodies in S-form lipopolysaccharide after acidic treatment of immobilized LPS on Western blot.
J. Endotoxin Res.
4:89-95.
|
| 23.
|
Pantophlet, R.,
L. Brade,
L. Dijkshoorn, and H. Brade.
1998.
Specificity of rabbit antisera against lipopolysaccharide of Acinetobacter.
J. Clin. Microbiol.
36:1245-1250[Abstract/Free Full Text].
|
| 24.
|
Rietschel, E. T., and H. Brade.
1992.
Bacterial endotoxins.
Sci. Am.
267:26-33.
|
| 25.
|
Rietschel, E. T.,
L. Brade,
B. Lindner, and U. Zähringer.
1992.
Biochemistry of lipopolysaccharides, p. 3-42.
In
D. C. Morrison, and J. L. Ryan (ed.), Bacterial endotoxic lipopolysaccharides, vol. I. Molecular biochemistry and cellular biology. CRC Press, Boca Raton, Fla.
|
| 26.
|
Rossau, R.,
A. van Landschoot,
M. Gillis, and J. de Ley.
1991.
Taxonomy of Moraxellaceae fam. nov., a new bacterial family to accommodate the genera Moraxella, Acinetobacter, and Psychrobacter and related organisms.
Int. J. Syst. Bacteriol.
41:310-319[Abstract/Free Full Text].
|
| 27.
|
Seifert, H.,
R. Baginski,
A. Schulze, and G. Pulverer.
1993.
The distribution of Acinetobacter species in clinical culture materials.
Zentbl. Bakteriol.
279:544-552.
|
| 28.
|
Seifert, H.,
L. Dijkshoorn,
P. Gerner-Smidt,
N. Pelzer,
I. Tjernberg, and M. Vaneechoutte.
1997.
Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods.
J. Clin. Microbiol.
35:2819-2825[Abstract].
|
| 29.
|
Seifert, H., and P. Gerner-Smidt.
1995.
Comparison of ribotyping and pulsed-field electrophoresis for molecular typing of Acinetobacter isolates.
J. Clin. Microbiol.
33:1402-1407[Abstract].
|
| 30.
|
Tjernberg, I., and J. Ursing.
1989.
Clinical strains of Acinetobacter classified by DNA-DNA hybridization.
APMIS
97:595-605[Medline].
|
| 31.
|
Towner, K. J.
1997.
Clinical importance and antibiotic resistance of Acinetobacter spp.
J. Med. Microbiol.
46:721-746[Abstract].
|
| 32.
|
Towner, K. J.,
E. Bergogne-Bérézin, and C. A. Fewson.
1991.
Acinetobacter: portrait of a genus, p. 1-24.
In
K. J. Towner, E. Bergogne-Bérézin, and C. A. Fewson (ed.), The biology of Acinetobacter: taxonomy, clinical importance, molecular biology, physiology, industrial relevance. Plenum Press, New York, N.Y.
|
| 33.
|
Vinogradov, E. V.,
R. Pantophlet,
L. Dijkshoorn,
L. Brade,
O. Holst, and H. Brade.
1996.
Structural and serological characterization of two O-specific polysaccharides from Acinetobacter.
Eur. J. Biochem.
239:602-610[Medline].
|
| 34.
|
Vinogradov, E. V.,
R. Pantophlet,
S. R. Haseley,
L. Brade,
O. Holst, and H. Brade.
1997.
Structural and serological characterization of the O-specific polysaccharide from lipopolysaccharide of Acinetobacter calcoaceticus strain 7 (DNA-group 1).
Eur. J. Biochem.
243:167-173[Medline].
|
| 35.
|
Weaver, R. E., and L. A. Actis.
1994.
Identification of Acinetobacter species.
J. Clin. Microbiol.
32:1833[Free Full Text].
|
Journal of Clinical Microbiology, June 1999, p. 1693-1698, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pantophlet, R., Severin, J. A., Nemec, A., Brade, L., Dijkshoorn, L., Brade, H.
(2002). Identification of Acinetobacter Isolates from Species Belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii Complex with Monoclonal Antibodies Specific for O Antigens of Their Lipopolysaccharides. CVI
9: 60-65
[Abstract]
[Full Text]
-
Pantophlet, R., Brade, L., Brade, H.
(2001). Generation and Serological Characterization of Murine Monoclonal Antibodies against O Antigens from Acinetobacter Reference Strains. CVI
8: 825-827
[Abstract]
[Full Text]
-
Pantophlet, R., Nemec, A., Brade, L., Brade, H., Dijkshoorn, L.
(2001). O-Antigen Diversity among Acinetobacter baumannii Strains from the Czech Republic and Northwestern Europe, as Determined by Lipopolysaccharide-Specific Monoclonal Antibodies. J. Clin. Microbiol.
39: 2576-2580
[Abstract]
[Full Text]
-
Vinogradov, E. V., Pantophlet, R., Brade, H., Holst, O.
(2001). Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter strain 96 (DNA group 11). Innate Immunity
7: 113-118
[Abstract]
-
Houang, E. T. S., Chu, Y. W., Leung, C. M., Chu, K. Y., Berlau, J., Ng, K. C., Cheng, A. F. B.
(2001). Epidemiology and Infection Control Implications of Acinetobacter spp. in Hong Kong. J. Clin. Microbiol.
39: 228-234
[Abstract]
[Full Text]
-
Pantophlet, R., Seifert, H., Brade, L., Brade, H.
(2000). Antibody Response to Lipopolysaccharide in Patients Colonized or Infected with an Endemic Strain of Acinetobacter Genomic Species 13 Sensu Tjernberg and Ursing. CVI
7: 293-295
[Abstract]
[Full Text]